Search results for " MCF-7 Cells"

showing 5 items of 5 documents

Gold nanostar–polymer hybrids for siRNA delivery: Polymer design towards colloidal stability and in vitro studies on breast cancer cells

2017

To overcome the low bioavailability of siRNA (small interfering RNA) and to improve their transfection efficiency, the use of non-viral delivery carriers is today a feasible approach to transform the discovery of these incredibly potent and versatile drugs into clinical practice. Polymer-modified gold nanoconstructs (AuNCs) are currently viewed as efficient and safe intracellular delivery carriers for siRNA, as they have the possibility to conjugate the ability to stably entrap and deliver siRNAs inside cells with the advantages of gold nanoparticles, which can act as theranostic agents and radiotherapy enhancers through laser-induced hyperthermia. In this study, AuNCs were prepared by coat…

3003siRNA deliverySmall interfering RNAPolymersMetal NanoparticlesPharmaceutical ScienceGold Colloid02 engineering and technologyPolyethylene Glycol01 natural sciencesPolyethylene GlycolsGold Colloidchemistry.chemical_compoundDrug Delivery SystemsMCF-7 CellDrug StabilityCoatingRNA Small InterferingPolymerDrug Carrierchemistry.chemical_classificationDrug CarriersTumorLipoic acidGold nanostarPolymer021001 nanoscience & nanotechnologyColloidal goldMCF-7 Cells0210 nano-technologyDrug carrierHydrophobic and Hydrophilic InteractionsBreast NeoplasmHumanBiological AvailabilityReproducibility of ResultBreast NeoplasmsNanotechnologyPolyethylene glycolengineering.materialSmall InterferingTransfection010402 general chemistryCell LineHydrophobic and Hydrophilic InteractionMetal NanoparticleCell Line TumorAmphiphileHumansGene SilencingParticle SizeGold nanostarsReproducibility of ResultsGold nanostars; Lipoic acid; MCF-7; PEG; PHEA; siRNA delivery; Biological Availability; Breast Neoplasms; Cell Line; Tumor; Drug Carriers; Drug Delivery Systems; Drug Stability; Gene Silencing; Gold; Gold Colloid; Humans; Hydrophobic and Hydrophilic Interactions; MCF-7 Cells; Metal Nanoparticles; Particle Size; Polyethylene Glycols; Polymers; RNA; Small Interfering; Reproducibility of Results; Transfection; 3003PHEAPEG0104 chemical scienceschemistrySettore CHIM/09 - Farmaceutico Tecnologico ApplicativoengineeringRNAGoldMCF-7Drug Delivery SystemInternational Journal of Pharmaceutics
researchProduct

New 1,2,4-oxadiazole nortopsentin derivatives with cytotoxic activity

2019

New analogs of nortopsentin, a natural 2,4-bis(3&prime

anti-cancer agentCell SurvivalAnti-cancer agentsPharmaceutical ScienceAntineoplastic AgentsAntiproliferative activity01 natural sciencesArticlechemistry.chemical_compoundStructure-Activity RelationshipMarine alkaloidsSettore BIO/10 - BiochimicaDrug DiscoveryMoietyHumansPharmacology Toxicology and Pharmaceutics (miscellaneous)lcsh:QH301-705.5Cell ProliferationIndole testMolecular Structure010405 organic chemistryAcridine orangeImidazoles2 4-oxadiazole derivativesnortopsentin analogs2 4-oxadiazole derivatives; Anti-cancer agents; Antiproliferative activity; Marine alkaloids; Nortopsentin analogs 1; Antineoplastic Agents; Caco-2 Cells; Cell Cycle Checkpoints; Cell Proliferation; Cell Survival; HCT116 Cells; Humans; Imidazoles; MCF-7 Cells; Molecular Structure; Structure-Activity RelationshipPhosphatidylserineCell Cycle CheckpointsNortopsentin analogs 1HCT116 CellsSettore CHIM/08 - Chimica Farmaceutica0104 chemical sciences124-oxadiazole derivative010404 medicinal & biomolecular chemistrychemistryBiochemistry124-oxadiazole derivativeslcsh:Biology (General)ApoptosisCell cultureCancer cellMCF-7 CellsMarine alkaloid2 4-oxadiazole derivativeCaco-2 CellsEthidium bromide
researchProduct

VEGF-targeted therapy stably modulates the glycolytic phenotype of tumor cells

2014

Abstract Anti-VEGF therapy perturbs tumor metabolism, severely impairing oxygen, glucose, and ATP levels. In this study, we investigated the effects of anti-VEGF therapy in multiple experimental tumor models that differ in their glycolytic phenotypes to gain insights into optimal modulation of the metabolic features of this therapy. Prolonged treatments induced vascular regression and necrosis in tumor xenograft models, with highly glycolytic tumors becoming treatment resistant more rapidly than poorly glycolytic tumors. By PET imaging, prolonged treatments yielded an increase in both hypoxic and proliferative regions of tumors. A selection for highly glycolytic cells was noted and this met…

Vascular Endothelial Growth Factor ACancer ResearchPathologymedicine.medical_specialtyNecrosismedicine.medical_treatmentAngiogenesis InhibitorsMice SCIDBiologySCIDAntibodies Monoclonal HumanizedAntibodiesCell LineTargeted therapyMiceRandom AllocationCell Line TumorNeoplasmsMonoclonalAngiogenesis Inhibitors; Animals; Antibodies Monoclonal Humanized; Bevacizumab; Cell Line Tumor; Female; Glycolysis; Humans; MCF-7 Cells; Mice; Mice Inbred BALB C; Mice SCID; Molecular Targeted Therapy; Neoplasms; Phenotype; Random Allocation; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor AssaysmedicineAnimalsHumansGlycolysisMolecular Targeted Therapycancer-cellAnti-VEGF therapyHumanizedInbred BALB CMED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIAMice Inbred BALB CTumorpositron emission tomography antiangiogenesis glucose metabolism hypoxiaXenograft Model Antitumor AssaysPhenotypeBlockadeBevacizumabVascular endothelial growth factor APhenotypeOncologyCell cultureMonoclonalMCF-7 CellsCancer researchMED/06 - ONCOLOGIA MEDICAFemalemedicine.symptomGlycolysis
researchProduct

Novel insulin receptor substrate 1 and 2 variants in breast and colorectal cancer

2013

The insulin/insulin-like growth factor pathway is involved in breast and colorectal cancer (CRC) development. In the present study, we analyzed the coding region and short intron-exon borders of the insulin receptor substrate 1 and 2 (IRS‑1 and IRS‑2) genes in 12 cell lines derived from breast cancer (BC), 14 cell lines derived from CRC and 33 primary CRCs. The nucleotide variants identified in BC were 3 in IRS‑1, 1 of which (p.Arg267Cys) was novel and with a pathogenic potential as predicted by in silico analysis and 6 in IRS‑2. Twenty‑one variants in IRS‑1 and 18 in IRS‑2 were identified in the CRC samples. These included 11 novel IRS‑1 variants detected exclusively in CRCs, which include…

Cancer ResearchInsulin Receptor Substrate ProteinsSettore MED/06 - Oncologia MedicaIn silicoMutation MissenseBreast NeoplasmsColorectal NeoplasmBiologymedicine.disease_causeFrameshift mutationBreast cancerBreast cancerMCF-7 CellCell Line TumormedicineHumansMissense mutationFrameshift MutationInsulin Receptor Substrate ProteinSequence DeletionGeneticsMutationCaco-2 CellPolymorphism GeneticCancerGenetic VariationInsulin receptor substrate 1ArticlesGeneral MedicineInsulin receptor substrate 2HCT116 Cellsmedicine.diseaseColorectal cancerIRS1Mutagenesis InsertionalCell Transformation NeoplasticHT29 CellOncologyHCT116 CellBreast cancer; Colorectal cancer; Insulin receptor substrate 1; Insulin receptor substrate 2; Breast Neoplasms; Caco-2 Cells; Cell Line Tumor; Cell Transformation Neoplastic; Colorectal Neoplasms; Female; Frameshift Mutation; Genetic Variation; HCT116 Cells; HT29 Cells; Humans; Insulin Receptor Substrate Proteins; MCF-7 Cells; Mutagenesis Insertional; Mutation Missense; Polymorphism Genetic; Sequence Deletion; Signal Transduction; Cancer Research; OncologyInsulin Receptor Substrate ProteinsMCF-7 CellsFemaleCaco-2 CellsColorectal NeoplasmsHT29 CellsBreast NeoplasmHumanSignal Transduction
researchProduct

Proton-irradiated breast cells: molecular points of view

2019

Abstract Breast cancer (BC) is the most common cancer in women, highly heterogeneous at both the clinical and molecular level. Radiation therapy (RT) represents an efficient modality to treat localized tumor in BC care, although the choice of a unique treatment plan for all BC patients, including RT, may not be the best option. Technological advances in RT are evolving with the use of charged particle beams (i.e. protons) which, due to a more localized delivery of the radiation dose, reduce the dose administered to the heart compared with conventional RT. However, few data regarding proton-induced molecular changes are currently available. The aim of this study was to investigate and descri…

breast cancer cDNA microarray gene signature proton therapy radiation Breast Breast Neoplasms Cell Line Tumor DNA Complementary Dose-Response Relationship Radiation Female Gene Expression Profiling Gene Expression Regulation Neoplastic Humans Inflammation MCF-7 Cells Oligonucleotide Array Sequence Analysis Phenotype Proton Therapy Radiation Tolerance Radiotherapy ProtonsDNA ComplementaryHealth Toxicology and Mutagenesismedicine.medical_treatmentBreast NeoplasmsCell fate determinationRadiation Tolerancegene signature03 medical and health sciences0302 clinical medicineBreast cancerbreast cancerCell Line TumorRegular Papermedicineproton therapyHumansRadiology Nuclear Medicine and imagingBreastClonogenic assayBiologyProton therapyOligonucleotide Array Sequence Analysis030304 developmental biologyInflammationcDNA microarray0303 health sciencesRadiotherapyChemistryGene Expression ProfilingBreast cancer; radiation; cDNA microarray; gene signature; proton therapyCancerDose-Response Relationship RadiationGene signaturemedicine.diseaseGene Expression Regulation NeoplasticGene expression profilingRadiation therapyradiationPhenotype030220 oncology & carcinogenesisMCF-7 CellsCancer researchFemaleProtons
researchProduct